Published in Vaccine on January 25, 2011
Prenatally acquired vitamin A deficiency alters innate immune responses to human rotavirus in a gnotobiotic pig model. J Immunol (2013) 0.88
Enhancement of recombinant adenovirus vaccine-induced primary but not secondary systemic and mucosal immune responses by all-trans retinoic acid. Vaccine (2014) 0.78
Induction of cellular and molecular immunomodulatory pathways by vitamin A and flavonoids. Expert Opin Biol Ther (2015) 0.77
Genipin-Crosslinked Gelatin-Based Emulgels: an Insight into the Thermal, Mechanical, and Electrical Studies. AAPS PharmSciTech (2015) 0.75
Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin-1β responses. Immunology (2016) 0.75
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6.13
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Marginal zone B cells. Annu Rev Immunol (2005) 3.32
Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest (1991) 2.97
Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis (2003) 2.12
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol (2009) 1.49
Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus. J Infect Dis (2001) 1.48
Marginal zone B cells in lymphocyte activation and regulation. Curr Opin Immunol (2005) 1.48
Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol (2007) 1.44
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Expression of toll-like receptors on B lymphocytes. Cell Immunol (2005) 1.33
Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine (2010) 1.16
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun (2005) 1.16
Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ (2004) 1.13
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol (2000) 1.10
The anti-tetanus immune response of neonatal mice is augmented by retinoic acid combined with polyriboinosinic:polyribocytidylic acid. Proc Natl Acad Sci U S A (2005) 1.09
Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord (2003) 1.07
Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol (2009) 1.06
Differential effects of simian immunodeficiency virus infection on immune inductive and effector sites in the rectal mucosa of rhesus macaques. Am J Pathol (2000) 1.05
Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol (2004) 1.02
Mechanism of mustard oil-induced skin inflammation in mice. Eur J Pharmacol (1997) 1.00
The role of substance P and calcitonin gene-related peptide in neurogenic plasma extravasation and vasodilatation in the rat. Neuroscience (1989) 0.97
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. Vaccine (2007) 0.95
Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology (2003) 0.94
Vitamin A levels and immunity in humans. Clin Diagn Lab Immunol (2002) 0.93
Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int Arch Allergy Immunol (2004) 0.92
Effects of anthocyanins and other phenolic compounds on the production of tumor necrosis factor alpha in LPS/IFN-gamma-activated RAW 264.7 macrophages. J Agric Food Chem (2002) 0.92
Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem Photobiol (2005) 0.92
Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun (2002) 0.90
Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine (2007) 0.89
Neonatal oil massage. Indian Pediatr (2003) 0.88
Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Can J Vet Res (1995) 0.87
Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem (2010) 0.86
Legionella pneumophila replication in macrophages inhibited by selective immunomodulatory effects on cytokine formation by epigallocatechin gallate, a major form of tea catechins. Infect Immun (2001) 0.85
A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin Immunol (2007) 0.84
Mustard oil induces a transient receptor potential vanilloid 1 receptor-independent neurogenic inflammation and a non-neurogenic cellular inflammatory component in mice. Neuroscience (2004) 0.84
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther (2010) 0.84
Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol (2007) 0.83
Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J Infect Dis (2004) 0.82
Response to influenza vaccine in adjuvant 65-4. J Hyg (Lond) (1975) 0.82
Estimating the demand for a preventive HIV vaccine: why we need to do better. Reliable estimates would help in achieving several policy and advocacy objectives. PLoS Med (2006) 0.81
Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D (2006) 0.79
All-trans retinoic acid biases immune response induced by DNA vaccine in a Th2 direction. Vaccine (2005) 0.78
Immune responses following cocktails of inactivated measles vaccine and Arachis hypogaea L. (groundnut) or Cocos nucifera L. (coconut) oils adjuvant. Vaccine (1996) 0.76
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol (2005) 1.00
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. Vaccine (2007) 0.95
The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci (2008) 0.92
Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine (2006) 0.91
Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog (2007) 0.90
Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses (2006) 0.90
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin (2007) 0.89
Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine (2007) 0.89
A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine (2006) 0.87
Maintenance of long-term immunological memory by low avidity IgM-secreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant. Vaccine (2004) 0.86
Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect Immun (2007) 0.84
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther (2010) 0.84
Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine. Clin Vaccine Immunol (2011) 0.84
Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology (2007) 0.83
Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol (2012) 0.78
Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant. Clin Vaccine Immunol (2009) 0.77
Maintenance of long-term immunological memory by Ig+CD45R+ non-plasma B cells following mucosal immunizations. Immunol Lett (2011) 0.76